Sponsors must translate clinical outcome assessments (COAs) into the target languages included within the footprint of their clinical trials. As clinical trials continue to grow in scope, it is not uncommon for trials to require COAs in 30-40 different languages. 

As scientific instruments, COAs must undergo a rigorous, iterative linguistic validation process to ensure their conceptual equivalency and cultural relevance for each translation. With careful consideration and knowledge of the best practices, sponsors can strategically avoid potential delays in this process. 

Download the whitepaper to learn more about:

• Key considerations for COA translations
• An overview of the linguistic validation process
• Timesaving strategies to minimise risks to study timelines
• Advice to sponsors for successful and timely translations